Interesting late breaker! Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression No difference in safety profile compared to placebo @RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt